Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06193954

VasoStar Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions

The goal of this project is to provide an improvement in wire performance to expedite crossing difficult lesions in the coronary vasculature.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Emory University, Atlanta, Georgia, United States

Loading trial locations.

About this study

This Early Feasibility Study (EFS) is proposed to evaluate the initial safety and efficacy of the VasoStar guidewire system to cross complex coronary vascular lesions in non-tortuous arterial segments which are resistant to crossing with a traditional interventional guidewire.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, over 18 years of age, presenting with at least one ischemia inducing lesion in a native coronary artery that is refractory to standard guidewire crossing. Chronic total occlusion (CTO) is defined as 100% coronary blockage for over a 3-month duration documented either by prior catheterization or by clinical evaluation
  • Suitable candidate for non-emergent, coronary angioplasty
  • Documented de-novo or restenotic coronary chronic total occlusion defined as a lesion with TIMI 0 flow for at least 90 days refractory to conventional guidewire crossing
  • Left ventricle ejection fraction > 20% within the last 12 months.
  • For antegrade chronic total occlusion procedures, activated clotting time (ACT) should be > 300 sec
  • Chronic total occlusion in a non-tortuous arterial segment
  • Voluntarily sign a Patient Informed Consent Form specific to the study.
  • Physically and mentally willing to comply with all study requirements.

Exclusion criteria

  • Successful target lesion crossing with a conventional wire system prior to enrollment
  • Prisoners.
  • Pregnancy
  • Patient has an active implantable.
  • Extensive dissection created by refractory guidewire
  • Severe ongoing congestive heart failure (New York Heart Association Class IV symptoms)
  • Active infection
  • Uncontrolled Hypertension (Systolic blood pressure > 180 mm) at the time of the procedure
  • History of severe reaction to contrast media
  • Recent myocardial infarction (within 2 weeks)
  • In-stent target lesion
  • Severe cerebrovascular disease including history of prior stroke or transient ischemic attack within 1 month at the time of the procedure
  • Saphenous vein graft (SVG) chronic total occlusion or an in-stent chronic total occlusion
  • Short life expectancy due to other illnesses such as cancer or pulmonary, hepatic or renal disease
  • Participation in another investigational protocol at the time of the procedure

Treatment and study plan

VasoStar guidewire system

Device

The VasoStar Vibrational Guidewire System vibrates longitudinally at the distal segment of a wire with an electromagnetic source.

Primary outcomes

  1. Number of participants with successful crossing of the target lesion with the VasoStar guidewire system

    Time frame: 1 day

  2. Incidence of Treatment-Emergent Serious Adverse Events

    Time frame: 30 days

    Number of device- or procedure- related serious adverse events

Secondary outcomes

  1. Improved 6-minute walk distance at 6 months following the VasoStar successful procedure

    Time frame: 6 months

  2. Improved 6-minute walk distance at 12 months following the VasoStar successful procedure

    Time frame: 12 months

  3. Improved score on the Seattle Angina Questionnaire at the 6-month visit compared to the score at baseline

    Time frame: 6 months

  4. Improved score on the Seattle Angina Questionnaire at the 12-month visit compared to the score at baseline

    Time frame: 12 months

  5. Reduced number of hospitalizations for cardiac symptoms within 1 year following the VasoStar procedure, compared to the reported number of hospitalizations following standard CTO procedures.

    Time frame: 1 year

  6. Reduced number of emergency room visits for cardiac symptoms within 1 year following the VasoStar procedure, compared to the reported number of hospitalizations following standard CTO procedures.

    Time frame: 1 year

Study contacts

Contact information is provided by the study sponsor or research team.

Mihaela Plesa

CONTACT

[email protected]

440 266 8226

Sponsors and collaborators

Lead sponsor

VasoStar, LLC

Industry

Collaborators

  • Summa Health

Registry information

Official study title

Evaluation of a Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions in Patients With Chronic Angina Refractory to Maximally Tolerated Guideline Directed Medical Therapy

Acronym: VST100

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jan 5, 2024
Registry last updated
Sep 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.